Biofrontera股价走高，该公司宣布评估Ameluz治疗中度至重度寻常痤疮的2b期临床试验的最后一名患者完成参与。该公司预计将在2026年第一季度收到顶级数据，并将在2026年第三季度向FDA提交调查结果，作为未来第三阶段计划的基础。

Biofrontera shares are trading higher after the company announced that the final patient in its Phase 2b clinical trial evaluating Ameluz for the treatment of moderate to severe acne vulgaris completed participation. The company expects to receive top-line data in Q1 2026 and will present findings to the FDA in Q3 2026 as the basis for a future Phase III program.